Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy

With increasing follow-up, DFS events are increasing defined by contralateral recurrence and non-breast cancer deaths with a trend for fewer distant recurrences. This may explain the limited association between DFS and overall survival with extended adjuvant endocrine therapy.